

## **NANOBIOTIX**

Société anonyme à directoire et conseil de surveillance au capital de 589.001,19 euros  
Siège social : 60 rue de Wattignies, 75012 Paris  
447 521 600 R.C.S. Paris

### **BRIEF SUMMARY OF THE COMPANY**

**Year ended december 31 2018**

#### **1.1. Company presentation**

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix's first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix's Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company's headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

## 1.2. Major milestones achieved during the year

### The key events of 2018 are chronologically summarized:

- **January 2018:** Nanobiotix associated with the Providence Cancer Institute to run an immunotherapeutic preclinical research in pancreatic cancer. This collaboration will provide essential preclinical data on the ability of NBTXR3 activated by radiotherapy to induce an antitumoral immune response.

Nanobiotix presented initial promising data from Phase I/II Liver trial evaluating NBTXR3 in Liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors at the American Society of Clinical Oncology Gastrointestinal Annual Meeting (ASCO GI). The results show that NBTXR3 was well tolerated with no adverse event related to NBTXR3 and no dose-limiting toxicity.

- **April 2018:** Nanobiotix and the University of Texas MD Anderson Cancer Center launched an immunotherapeutic preclinical research using NBTXR3 and Nivolumab in Lung cancer. The main objective of this project, is to provide preclinical data using NBTXR3 activated by radiotherapy plus anti PD-1 Nivolumab;

Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway at the American Association for Cancer Research (AACR). These observations support the rationale for using NBTXR3 with radiation therapy in combination with immunotherapeutic agents and/or STING agonist to transform tumors into *in situ* cancer vaccine;

Nanobiotix was selected to enter Euronext's Tech 40 label, recognizing the best performing Tech SMEs listed on Euronext markets. An independent group of European experts annually selects 40 great companies on the basis of their business, financial and stock market performance;

- **May 2018:** Nanobiotix and Weill Cornell Medicine partnered to perform preclinical studies to evaluate the impact of NBTXR3 cGAS-STING pathway in mammary cancers. Data generated from this collaboration could provide support for the assertion that NBTXR3 activated by radiotherapy can increase the anti-tumor response compared to radiotherapy alone;

- **June 2018:** Nanobiotix announced positive results from its Phase II/III clinical trial of NBTXR3 in patients with locally advanced Soft Tissue Sarcoma. The trial achieved its primary endpoint with a pathological complete response rate. It also achieved its secondary endpoint in operability. NBTXR3 demonstrated clinical meaningful benefits for such patients versus standard of care. The data also showed that NBTXR3 was well tolerated. The randomized trial validated the first-in-class mode of action of NBTXR3.

- **July 2018:** Nanobiotix signed a €40M non-dilutive agreement with the European Investment Bank. This agreement will allow the Company to borrow up to €40M through loans before July 26, 2020 subject to achieving a set of agreed performance criteria.

- **September 2018:** Nanobiotix provided an update on the Head and Neck Phase I Trial with NBTXR3 data presented at ImmunoRad 2018. The Phase I Trial focus on elderly and frail patients ineligible for cisplatin or intolerant to cetuximab. The data show the potential impact on survival in this patient population;

Nanobiotix presented positive results from its phase II/III clinical trial of NBTXR3 with Soft Tissue Sarcoma and other ongoing phase I/II at European Society for Medical Oncology (ESMO) and American Society for Radiation Oncology (ASTRO);

- **October 2018:** Nanobiotix received the first tranche disbursement of €16M financed by the European Investment Bank. The financing agreement will enable Nanobiotix to accelerate both the development of its

NBTXR3 clinical trial in Head and Neck cancer indication and will support Nanobiotix's European go-to-market strategy;

Positive results from phase II/III for NBTXR3 in Soft Tissue Sarcoma was presented by Dr Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at Institut Curie – Paris, presented for the European Society for Medical Oncology (ESMO). NBTXR3 is the first radiotherapy enhancer to demonstrate clinically meaningful benefit for patients with locally advanced Soft Tissue Sarcoma compared to radiotherapy alone

**--oo0oo--**